Scarica l'app Stockscreener
27.55
7.40%
1.82
Precedente Chiudi:
$25.73
Aprire:
$26.02
Volume 24 ore:
42,783
Relative Volume:
0.09
Capitalizzazione di mercato:
$383.08M
Reddito:
-
Utile/perdita netta:
$-19.48M
Rapporto P/E:
-18.82
EPS:
-1.4641
Flusso di cassa netto:
$-8.59M
1 W Prestazione:
-4.71%
1M Prestazione:
-4.77%
6M Prestazione:
+134.59%
1 anno Prestazione:
+124.67%
Intervallo 1D:
$25.90
$27.83
Intervallo di 1 settimana:
$25.68
$30.12
Portata 52W:
$7.78
$34.10
Greenwich Lifesciences Inc Stock (GLSI) Company Profile
Nome
Greenwich Lifesciences Inc
Settore
Industria
Telefono
203-434-3290
Indirizzo
3992 BLUEBONNET DR, BUILDING 14, STAFFORD
Compare GLSI vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GLSI
Greenwich Lifesciences Inc
|
27.65 | 356.48M | 0 | -19.48M | -8.59M | -1.4641 |
|
VRTX
Vertex Pharmaceuticals Inc
|
495.97 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
799.96 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
846.57 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.38 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
350.03 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Greenwich Lifesciences Inc Stock (GLSI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-20 | Iniziato | Noble Capital Markets | Outperform |
| 2021-09-01 | Iniziato | H.C. Wainwright | Buy |
Greenwich Lifesciences Inc Borsa (GLSI) Ultime notizie
Aug Update: Will Greenwich LifeSciences Inc stock benefit from M A2025 Winners & Losers & Community Consensus Trade Signals - baoquankhu1.vn
Analyst Upgrade: Is Lavoro Limiteds growth already priced inJuly 2025 Highlights & Low Risk Growth Stock Ideas - baoquankhu1.vn
HC Wainwright Issues Positive Forecast for GLSI Earnings - Defense World
Valuation Update: Can Greenwich LifeSciences Inc expand into new marketsJuly 2025 Momentum & Weekly Momentum Stock Picks - baoquankhu1.vn
Greenwich LifeSciences (NASDAQ:GLSI) Trading Down 6.7% – Time to Sell? - Defense World
Greenwich LifeSciences: Strengthened Liquidity and Robust GP2 Data Support Reiterated Buy and $50 Target - TipRanks
Discipline and Rules-Based Execution in GLSI Response - Stock Traders Daily
Patel, Greenwich Lifesciences CEO, buys $63k in GLSI stock By Investing.com - Investing.com Nigeria
Will Greenwich LifeSciences Inc. benefit from current market trendsTrade Signal Summary & Free Real-Time Volume Trigger Notifications - mfd.ru
Greenwich LifeSciences reports $12.5 million cash balance - Investing.com
Greenwich LifeSciences reports $12.5 million cash balance By Investing.com - Investing.com Nigeria
Greenwich LifeSciences provides update on Flamingo-01 cash burn rate and financing strategy - marketscreener.com
Greenwich LifeSciences, Inc. Reports Positive Financial Updates and Progress on FLAMINGO-01 Phase III Trial - Quiver Quantitative
Greenwich Lifesciences Provides Update On Flamingo-01 Cash Burn Rate And Financing Strategy - TradingView
Biotech Greenwich LifeSciences raises $7M in 3 weeks for breast cancer trial - Stock Titan
FDA Approval Boosts Greenwich LifeSciences Stock Sharply - timothysykes.com
Treasury Yields: Will Greenwich LifeSciences Inc benefit from current market trendsMarket Volume Report & Low Risk Entry Point Tips - baoquankhu1.vn
Greenwich: GP2 Vaccine MilestoneWhat FDA Manufacturing Approval Means For Investors - Seeking Alpha
Insiders of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) must be frustrated after market cap dropped US$50m since recent purchases - Yahoo Finance
Behavioral Patterns of GLSI and Institutional Flows - Stock Traders Daily
FDA approves commercial GP2 lot for Greenwich’s breast cancer trial By Investing.com - Investing.com Canada
Why Did Greenwich Lifesciences Stock Soar Pre-Market Today? - Menafn.com
Why Did Greenwich LifeSciences Stock Soar Pre-Market Today? - Asianet Newsable
GLSI Stock Surges Pre-Market On Clearing FDA Manufacturing Step For Its Breast Cancer Trial - Stocktwits
Greenwich LifeSciences stock soars after FDA approves commercial GP2 in trial - Investing.com Canada
Greenwich gets FDA nod for commercially made product candidate - Seeking Alpha
Greenwich LifeSciences surges as FDA clears supplies for breast cancer trial - TradingView
Greenwich LifeSciences Announces FDA Approves Use of Commercially Manufactured GP2 in FLAMINGO-01 - The Manila Times
FDA approves first GP2 batch for breast cancer trial, 200,000 doses - Stock Titan
Head to Head Contrast: Greenwich LifeSciences (NASDAQ:GLSI) & Vertex Pharmaceuticals (NASDAQ:VRTX) - Defense World
Insider Buying: Greenwich LifeSciences (NASDAQ:GLSI) CEO Acquires 1,800 Shares of Stock - MarketBeat
Greenwich LifeSciences CEO Patel buys $53,694 in GLSI stock By Investing.com - Investing.com Canada
Greenwich LifeSciences stockholders reelect board and auditor - MSN
The $69B Precision Pivot: Why Biomarker Platforms are Igniting a New Oncology Gold Rush - Baystreet.ca
Insider Buying: Greenwich LifeSciences (NASDAQ:GLSI) CEO Purchases 2,900 Shares of Stock - MarketBeat
Greenwich LifeSciences CEO Patel buys $79,866 in GLSI stock By Investing.com - Investing.com South Africa
Greenwich LifeSciences CEO Patel buys $79,866 in GLSI stock - Investing.com
Greenwich LifeSciences (GLSI) Price Target Increased by 13.10% to 48.45 - Nasdaq
Chart Watch: Will Greenwich LifeSciences Inc stock benefit from commodity pricesJuly 2025 Reactions & Entry Point Confirmation Signals - Bộ Nội Vụ
Technical Analysis: Is Greenwich LifeSciences Inc stock ready for breakoutTrade Exit Summary & Reliable Price Action Trade Plans - Bộ Nội Vụ
Why is GLSI stock rising today? - MSN
HER2-Positive Breast Cancer Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Roche Pharma AG, Dizal Pharma, Greenwich LifeSciences, Ambrx - The Globe and Mail
Will Greenwich LifeSciences Inc. stock outperform growth indexesJuly 2025 Selloffs & Accurate Intraday Trading Signals - Улправда
Why Greenwich LifeSciences Inc. stock is a must watch in 2025Volume Weighted Average Price & Smart Beta Strategies That Actually Work - Улправда
How $594B in Precision Tech is Cracking the Metastatic Cancer Code - The Globe and Mail
Snehal Patel Buys Handful Of Shares In Greenwich LifeSciences - simplywall.st
Greenwich LifeSciences (NASDAQ:GLSI) CEO Snehal Patel Acquires 4,300 Shares - Defense World
Will Greenwich LifeSciences Inc. stock benefit from upcoming earnings reports2026 world cup usa national team group stage star players transition play group prediction preview - ulpravda.ru
A US$74m drop in the market cap of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) is not what insiders like to see after purchasing shares recently - simplywall.st
Insider Buying: Greenwich LifeSciences (NASDAQ:GLSI) CEO Acquires 4,300 Shares of Stock - MarketBeat
Head-To-Head Analysis: Greenwich LifeSciences (NASDAQ:GLSI) vs. Avalon GloboCare (NASDAQ:ALBT) - Defense World
Greenwich Lifesciences Inc Azioni (GLSI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Greenwich Lifesciences Inc Azioni (GLSI) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Patel Snehal | CEO and CFO |
Jan 12 '26 |
Buy |
27.54 |
2,900 |
79,866 |
5,602,302 |
| Patel Snehal | CEO and CFO |
Dec 31 '25 |
Buy |
21.36 |
4,300 |
91,848 |
5,599,402 |
| Patel Snehal | CEO and CFO |
Dec 30 '25 |
Buy |
21.73 |
2,900 |
63,017 |
5,595,102 |
| Patel Snehal | CEO and CFO |
Dec 18 '25 |
Buy |
12.62 |
4,100 |
51,742 |
5,592,202 |
| Patel Snehal | CEO and CFO |
Nov 25 '25 |
Buy |
8.37 |
4,600 |
38,502 |
5,588,102 |
| Patel Snehal | CEO and CFO |
Nov 07 '25 |
Buy |
8.43 |
10,600 |
89,358 |
5,583,502 |
| Patel Snehal | CEO and CFO |
Oct 31 '25 |
Buy |
9.26 |
2,300 |
21,298 |
5,572,902 |
| Patel Snehal | CEO and CFO |
Apr 25 '25 |
Buy |
9.88 |
3,600 |
35,568 |
5,570,602 |
| Patel Snehal | CEO and CFO |
Apr 17 '25 |
Buy |
8.98 |
5,400 |
48,492 |
5,567,002 |
| Patel Snehal | CEO and CFO |
Apr 07 '25 |
Buy |
9.10 |
3,600 |
32,760 |
5,561,602 |
0.71%
1.30%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):